<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50826">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02444533</url>
  </required_header>
  <id_info>
    <org_study_id>14-007071</org_study_id>
    <nct_id>NCT02444533</nct_id>
  </id_info>
  <brief_title>EXPAREL® for Pain After Tonsillectomy</brief_title>
  <official_title>A Phase IV Randomize, Single-Blind, Trial of Liposomal Bupivacaine (EXPAREL®) for Pain Control in Post-Tonsillectomy Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether liposomal bupivacaine (long acting
      injectable anesthetic) provides greater post operative pain relief compared to the standard
      post operative pain regiment for tonsillectomy patients.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Score (pain scores on a 0/10 scale)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Patient will record pain scores on a 0/10 scale over a 2 week time frame</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain medication usage (milligrams used)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Patient will record pain medication usage in milligrams used of Tylenol, Ibuprofen, and Oxycodone over a 2 week time frame</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral intake (patient recorded oral intake)</measure>
    <time_frame>1 week</time_frame>
    <description>Patient will record oral intake over one week</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient complication ( allergic reaction, swallowing dysfunction, hospital admission related to the study drug)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Patients will be monitored for drug related complications such as allergic reaction, swallowing dysfunction, hospital admission related to the study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-tonsillectomy bleeding rate</measure>
    <time_frame>4 weeks</time_frame>
    <description>The rate of post-tonsillectomy bleeding will be recorded and compared to the arm who did not receive the injection.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Tonsillectomy</condition>
  <condition>Tonsillitis</condition>
  <condition>Post-operative Pain</condition>
  <arm_group>
    <arm_group_label>Liposomal Bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient will receive liposomal bupivacaine in the tonsillar fossae after tonsillectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patient will not be given any medications in the tonsillar fossae after tonsillectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Bupivacaine</intervention_name>
    <description>Injection of 8 ml of liposomal bupivacaine total in the tonsillar fossae after tonsillectomy.</description>
    <arm_group_label>Liposomal Bupivacaine</arm_group_label>
    <other_name>Exparel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of recurrent tonsillitis or bilateral tonsillar hypertrophy requiring
             bilateral tonsillectomy

          -  Male or female with age ≥ 18 years

          -  Willing and able to understand and provide written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Price, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <lastchanged_date>May 13, 2015</lastchanged_date>
  <firstreceived_date>May 8, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Daniel L. Price, M.D.</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>Liposomal Bupivacaine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Tonsillitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
